Taroh Satoh
About
Taroh Satoh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Taroh Satoh has authored 303 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Oncology, 172 papers in Pulmonary and Respiratory Medicine and 75 papers in Surgery. Recurrent topics in Taroh Satoh's work include Gastric Cancer Management and Outcomes (127 papers), Colorectal Cancer Treatments and Studies (115 papers) and Lung Cancer Treatments and Mutations (41 papers). Taroh Satoh is often cited by papers focused on Gastric Cancer Management and Outcomes (127 papers), Colorectal Cancer Treatments and Studies (115 papers) and Lung Cancer Treatments and Mutations (41 papers). Taroh Satoh collaborates with scholars based in Japan, United States and South Korea. Taroh Satoh's co-authors include Atsushi Ohtsu, Hyun Cheol Chung, Yung‐Jue Bang, Yasushi Omuro, Eric Van Cutsem, Yoon‐Koo Kang, Akira Sawaki, Julie Hill, Е. С. Куликов and A. Feyereislova and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Taroh Satoh
281 papers receiving 12.4k citations
Hit Papers
Peers
Taroh Satoh
Heike I. Grabsch United Kingdom
Josef Rüschoff Germany
Karin Haustermans Belgium
Shirley Zhu United States
Irıs D. Nagtegaal Netherlands
Ronald Simon Germany
Takayuki Yoshino Japan
Young‐Hyuck Im South Korea
Soichiro Ishihara Japan
Antoine Hollebecque France
Citations per year, relative to Taroh Satoh Taroh Satoh (= 1×)
peers
Heike I. Grabsch
Countries citing papers authored by Taroh Satoh
Since
Specialization
Citations
This map shows the geographic impact of Taroh Satoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taroh Satoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taroh Satoh more than expected).
Fields of papers citing papers by Taroh Satoh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Taroh Satoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taroh Satoh. The network helps show where Taroh Satoh may publish in the future.
Co-authorship network of co-authors of Taroh Satoh
This figure shows the co-authorship network connecting the top 25 collaborators of Taroh Satoh. A scholar is included among the top collaborators of Taroh Satoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taroh Satoh. Taroh Satoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sakai, Daisuke, Shigenori Kadowaki, Ryohei Kawabata, et al.. (2025). Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Journal of Clinical Oncology. 43(19). 2196–2207.
2.
Janjigian, Yelena Y., Michael Cecchini, Kohei Shitara, et al.. (2025). Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology. 9(9). e2400456–e2400456.
3.
Kotani, Daisuke, Hideaki Bando, Hiroya Taniguchi, et al.. (2024). Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).. Journal of Clinical Oncology. 42(16_suppl). 3585–3585.
4.
Miyagaki, Hiromichi, Masahiro Goto, Shunji Endo, et al.. (2024). Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial.. Journal of Clinical Oncology. 42(16_suppl). 4031–4031.
5.
Kawamoto, Yasuyuki, Yoshito Komatsu, Shunsuke Kondo, et al.. (2024). Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future Oncology. 20(26). 1901–1907.
6.
Kawakami, Hisato, Daichi Maeda, Daisuke Sakai, et al.. (2023). The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. Scientific Reports. 13(1). 5652–5652.
7.
Kato, Takeshi, Atsuo Takashima, Taroh Satoh, et al.. (2023). P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study. Annals of Oncology. 34. S21–S22.
8.
Li, Bob T., Funda Meric‐Bernstam, Aditya Bardia, et al.. (2023). 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Annals of Oncology. 34. S459–S460.
9.
Kimura, Yutaka, Hisato Kawakami, Shigeyuki Tamura, et al.. (2023). Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials. Gastric Cancer. 26(5). 788–797.
10.
Kawakami, Hisato, Kazuhiro Nishikawa, Toshio Shimokawa, et al.. (2022). Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease. Cancers. 14(22). 5673–5673.
11.
Noda, Takehiro, Hidekazu Takahashi, Mitsuyoshi Tei, et al.. (2022). Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi‐institutional retrospective study. Annals of Gastroenterological Surgery. 7(3). 479–490.
12.
Maeda, Daichi, Yuki Sato, Daisuke Sakai, et al.. (2021). Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital. Cancers. 13(5). 1121–1121.
13.
Muro, Kei, Takashi Kojima, Toshikazu Moriwaki, et al.. (2021). Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus. 19(1). 137–145.
14.
Nishida, Naohiro, Tsuyoshi Hata, Shiki Fujino, et al.. (2021). Specific activation of glycolytic enzyme enolase 2 in BRAF V600E‐mutated colorectal cancer. Cancer Science. 112(7). 2884–2894.
15.
Kotaka, Masahito, Shigeyoshi Iwamoto, Hironaga Satake, et al.. (2020). Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). International Journal of Clinical Oncology. 25(8). 1515–1522.
16.
Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2019). Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open. 4(6). e000590–e000590.
17.
Konno, Masamitsu, Jun Koseki, Ayumu Asai, et al.. (2019). Distinct methylation levels of mature microRNAs in gastrointestinal cancers. Nature Communications. 10(1). 3888–3888.
18.
Toratani, Masayasu, Masamitsu Konno, Ayumu Asai, et al.. (2018). A Convolutional Neural Network Uses Microscopic Images to Differentiate between Mouse and Human Cell Lines and Their Radioresistant Clones. Cancer Research. 78(23). 6703–6707.
19.
Satoh, Taroh. (2017). Nivolumab (ONO-4538/BMS-936558) after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. 204.
20.
Okamoto, Isamu, Hiroyasu Kaneda, Taroh Satoh, et al.. (2010). Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 9(10). 2825–2833.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Heike I. Grabsch Breakdown of academic impact, for papers by Josef Rüschoff Breakdown of academic impact, for papers by Karin Haustermans Breakdown of academic impact, for papers by Shirley Zhu Breakdown of academic impact, for papers by Irıs D. Nagtegaal Breakdown of academic impact, for papers by Ronald Simon Breakdown of academic impact, for papers by Takayuki Yoshino Breakdown of academic impact, for papers by Young‐Hyuck Im Breakdown of academic impact, for papers by Soichiro Ishihara Breakdown of academic impact, for papers by Antoine Hollebecque